BURLINGTON, Mass., June 21, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will participate in the following upcoming investor conferences:
- Janney Capital Markets Boston Healthcare 1X1 Corporate Access Day on Thursday, June 27, 2013 in Boston, MA
- Piper Jaffray Catalyst Symposium: Emerging Talent in Biopharma on Tuesday, July 9, 2013 Boston, MA
The format of these upcoming conferences does not include formal presentations. Coronado will only be participating in one-on-one meetings.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.
CONTACT: Lucy Lu, MD, Executive Vice President & Chief Financial Officer Coronado Biosciences, Inc. 781-652-4525; email@example.com Marcy Nanus, Vice President The Trout Group, LLC. 646-378-2927; firstname.lastname@example.org Susan Forman Dian Griesel Inc. 212-825-3210; email@example.com